Background
Lenacapavir (LEN) is the first-in-class twice-yearly long-acting HIV-1 capsid inhibitor approved for treating multidrug-resistant HIV-1, as well as for pre-exposure prophylaxis (PrEP) in people who could benefit from PrEP. In heavily treatment-experienced people with HIV (PWH), LEN resistance mutations have been observed in the context of LEN functional monotherapy. One such mutation, T107N, is associated with a 4-fold decrease in LEN susceptibility. Other T107 polymorphisms, including T107A and T107S, which occur in 1–2% of circulating HIV-1 sequences, have unknown impact on LEN susceptibility. Here, we are describing the phenotypic susceptibility of viral isolates with T107 polymorphism.
Methods
Clinical isolates (CI) with either wild-type (WT) T107T (n=5) or polymorphic residues T107A (n=5), T107S (n=7), and corresponding site-directed mutants (SDM) constructed from isolates to express the known LEN minor resistance mutation T107N (n=8) were cloned into the pXXLAI infectious clone and transfected into HEK293T cells. Viral supernatants were used to infect Rev-CEM-GFP/Luc HIV reporter cells in the presence of LEN dose titration, with luminescence data used to calculate the half-maximal concentration (EC50) and fold-change (FC; Microsoft Excel and XLFit). The known N74D CA mutant was used as a resistant control for comparison.
Results
LEN susceptibility data were obtained for all isolates tested. The XXLAI WT reference showed an average LEN EC50 of 78 pM. LEN susceptibility of the resistant control N74D had a mean LEN EC50 FC of 12.4 from the WT control. In comparison to the WT reference control, the CIs with the WT (T107T) residue, T107A residue, and T107S residue had a mean LEN EC50 FC (SD) of 1.3 (0.4), 0.8 (0.4), and 1.3 (0.5), respectively. In contrast, only the SDMs with T107N showed some phenotypic resistance with a mean LEN EC50 FC (SD) of 4.9 (3.4). When comparing the T107N SDM to the CIs from which they had been constructed, we observed a mean LEN EC50 increase of 3.3-fold (SD 1.8).
Conclusions
Viruses harboring the polymorphisms T107A and T107S showed full susceptibility to LEN, in contrast to viruses with T107N. These data suggest that the presence of the T107A and T107S polymorphisms alone in HIV-1 sequences from PWH are unlikely to affect the effectiveness of LEN in people being treated for HIV.